Evidence map›Paper›PMID 33100921›Full record

ArticleJournal of biomolecular techniques : JBT2020

Laboratory Optimization Tweaks for Sanger Sequencing in a Resource-Limited Setting.

Chika K Onwuamah, Azuka P Okwuraiwe, Rahaman A Ahmed, Judith O Sokei, Jamda Ponmak, Leona C Okoli, Brian A Kagurusi, Joseph Anejo-Okopi

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomolecular techniques : JBT, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Chika K OnwuamahCenter for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba 101212, Lagos, Nigeria.
Azuka P OkwuraiweCenter for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba 101212, Lagos, Nigeria.
Rahaman A AhmedCenter for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba 101212, Lagos, Nigeria.
Judith O SokeiCenter for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba 101212, Lagos, Nigeria.
Jamda PonmakCenter for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba 101212, Lagos, Nigeria.
Leona C OkoliCenter for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba 101212, Lagos, Nigeria.
Brian A KagurusiUniversity of Maryland, Baltimore, Maryland, USA; and.
Joseph Anejo-OkopiAIDS Prevention Initiative in Nigeria, Jos, University Teaching Hospital, Jos, Nigeria.
Nigerian Institute of Medical Research · NGJos University Teaching Hospital · NGUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite various challenges that hinder the implementation of high-tech molecular methods in resource-limited settings, we have been able to implement and achieve International Organization for Standardization 15189:2012 accreditation for genotypic HIV drug resistance testing in our facility. At the Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Nigeria has recorded a high sequencing success rate and good quality sequence data. This was achieved by optimizing laboratory processes from 2008 to the current date. We have optimized sample preparation, RT-PCR, several post-PCR processes, and the cycle sequencing to improve the sensitivity of amplification even with limited plasma samples and low viral copy numbers. The optimized workflow maximizes output, minimizes reagent wastage, and achieves substantial cost savings without compromising the quality of the sequence data. Our performance at our last external quality assurance program is a testimonial to the efficiency of the workflow. For the 5-sample panel, each with 67-68 mutation points evaluated, we scored 100% for all 5 specimens. Our optimized laboratory workflow is thus documented to support laboratories and to help researchers achieve excellent results the first time and eliminate contamination while minimizing the wastage of costly sequencing reagents.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsHumansLaboratoriesNigeriaQuality ControlReal-Time Polymerase Chain ReactionReference StandardsRNA, ViralSequence Analysis, DNAWorkflowRNA, Viralbiomedical research · HIV drug resistance · laboratory workflow · reverse transcriptase polymerase chain reaction

Identifiers

PMID33100921
PMCPMC7566614
OpenAlexW3093790905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.